Enhanced TLR4 expression on colon cancer cells after chemotherapy promotes cell survival and epithelial-mesenchymal transition through phosphorylation of GSK3?

Anticancer Research

Volumn 36, Issue 7, 2016, Pages 3383-3394

  Chung, Yoon Hee ^a   Kim, Daejin ^b  

^a Chung Ang University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Colorectal cancer; EMT; Epithelial mesenchymal transition; GSK 3; TLR4

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; FLUOROURACIL; GLYCOGEN SYNTHASE KINASE 3BETA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PROTEIN BCL 2; SURVIVIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; X LINKED INHIBITOR OF APOPTOSIS; GSK3B PROTEIN, HUMAN; PLATINUM COMPLEX; TLR4 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; UPREGULATION; BIOSYNTHESIS; COLONIC NEOPLASMS; DRUG EFFECTS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

APOPTOSIS; CELL SURVIVAL; COLONIC NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLUOROURACIL; GLYCOGEN SYNTHASE KINASE 3 BETA; HCT116 CELLS; HT29 CELLS; HUMANS; LIPOPOLYSACCHARIDES; ORGANOPLATINUM COMPOUNDS; PHOSPHORYLATION; TOLL-LIKE RECEPTOR 4;

EID: 84992070829     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, Qin GJ, Liang G, Li JN, Han XF and Liu DX: Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol 46: 2876-2884, 2009.
2. Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, Nagai S, Wada J, Yanai K, Koga K, Sato N, Kubo M, Tanaka M, Onishi H and Katano M: Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway. J Surg Oncol 100: 725-731, 2009.
3. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, Kudo E, Shimada M and Sano T: High expression of toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 102: 908-915, 2010.
4. Yu LX, Yan HX, Liu Q, Yang W, Wu HP, Dong W, Tang L, Lin Y, He YQ, Zou SS, Wang C, Zhang HL, Cao GW, Wu MC and Wang HY: Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52: 1322-1333, 2010.
5. González-Reyes S, Marín L, González L, González LO, del Casar JM, Lamelas ML, González-Quintana JM and Vizoso FJ: Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 10: 665, 2010.
6. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, Bouchier-Hayes D and Dong Z: Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 101: 415-422, 2002.
7. Arkenau HT, Bermann A, Rettig K, Strohmeyer G, Porschen R and Arbeitsgemeinschaft Gastrointestinale Onkologie: 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol 14: 395-399, 2003.
8. Davoodi H, Hashemi SR and Seow HF: 5-Fluorouracil induce the expression of TLR4 on HCT116 colorectal cancer cell line expressing different variants of TLR4. Iran J Pharm Res 12: 453-460, 2013.
9. Cohen P and Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3: 479-487, 2004.
10. Kim JS, Yeo S, Shin DG, Bae YS, Lee JJ, Chin BR, Lee CH and Baek SH: Glycogen synthase kinase 3and catenin pathway is involved in toll-like receptor 4-mediated NADPH oxidase 1 expression in macrophages. FEBS J 277: 2830-2837, 2010.
11. Wang H, Garcia CA, Rehani K, Cekic C, Alard P, Kinane DF, Mitchell T and Martin M: IFN-production by TLR4-stimulated innate immune cells is negatively regulated by GSK3-beta. J Immunol 181: 6797-6802, 2008.
12. Rayasam GV, Tulasi VK, Sodhi R, Davis JA and Ray A: Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 156: 885-898, 2009.
13. Jope RS and Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102, 2004.
14. Frame S, Cohen P and Biondi RM: A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7: 1321-1327, 2001.
15. Ma C, Wang J, Gao Y, Gao TW, Chen G, Bower KA, Odetallah M, Ding M, Ke Z and Luo J: The role of glycogen synthase kinase 3 in the transformation of epidermal cells. Cancer Res 67: 7756-7764, 2007.
16. Soto-Cerrato V, Viñals F, Lambert JR, Kelly JA and Pérez-Tomás R: Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3 activity in human breast cancer cells. Mol Cancer Ther 6: 362-369, 2007.
17. Zhou Y, Uddin S, Zimmerman T, Kang JA, Ulaszek J and Wickrema A: Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma 49: 1945-1953, 2008.
18. Cao Q, Lu X and Feng YJ: Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 16: 671-677, 2006.
19. Sodhi CP, Shi XH, Richardson WM, Grant ZS, Shapiro RA, Prindle T Jr, Branca M, Russo A, Gribar SC, Ma C and Hackam DJ: Toll-like receptor-4 inhibits enterocyte proliferation via impaired catenin signaling in necrotizing enterocolitis. Gastroenterology 138: 185-196, 2010.
20. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y and Minamoto T: Deregulated GSK3 activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334: 1365-1373, 2005.
21. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA and Billadeau DD: Glycogen synthase kinase-3 participates in nuclear factor B-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 65: 2076-2081, 2005.
22. Wilson W III and Baldwin AS: Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3/ in pancreatic cancer. Cancer Res 68: 8156-8163, 2008.
23. Grassilli E, Narloch R, Federzoni E, Ianzano L, Pisano F, Giovannoni R, Romano G, Masiero L, Leone BE, Bonin S, Donada M, Stanta G, Helin K and Lavitrano M: Inhibition of GSK3 bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Clin Cancer Res 19: 3820-3831, 2013.
24. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S and Ferri LE: LPS-induced TLR4 signaling in human colorectal cancer cells increases 1 integrin-mediated cell adhesion and liver metastasis. Cancer Res 71: 1989-1998, 2011.
25. Hetman M, Cavanaugh JE, Kimelman D and Xia Z: Role of glycogen synthase kinase-3 in neuronal apoptosis induced by trophic withdrawal. J Neurosci 20: 2567-2574, 2000.
26. Ren F, Duan Z, Cheng Q, Shen X, Gao F, Bai L, Liu J, Busuttil RW, Kupiec-Weglinski JW and Zhai Y: Inhibition of glycogen synthase kinase 3 ameliorates liver ischemia reperfusion injury by way of an interleukin-10-mediated immune regulatory mechanism. Hepatology 54: 687-696, 2011.
27. Manoukian AS and Woodgett JR: Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res 84: 203-229, 2002.
28. Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, Laghi L, Barberis MC, Sessa F, Noonan DM and Albini A: The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med 8: 112, 2010.
29. Eiró N, González L, González LO, Fernandez-Garcia B, Andicoechea A, Barbón E, García-Muñiz JL and Vizoso FJ: Tolllike receptor-4 expression by stromal fibroblasts is associated with poor prognosis in colorectal cancer. J Immunother 36: 342-349, 2013.
30. Doan HQ, Bowen KA, Jackson LA and Evers BM: Toll-like receptor 4 activation increases AKT phosphorylation in colon cancer cells. Anticancer Res 29: 2473-2478, 2009.
31. Niedzielska I, Niedzielski Z, Tkacz M, Orawczyk T, Ziaja K, Starzewski J, Mazurek U and Markowski J: Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer. J Physiol Pharmacol 60(Suppl 1): 65-71, 2009.
32. Rakoff-Nahoum S and Medzhitov R: Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317: 124-127, 2007.
33. Li H, Sun X, LeSage G, Zhang Y, Liang Z, Chen J, Hanley G, He L, Sun S and Yin D: arrestin 2 regulates Toll-like receptor 4-mediated apoptotic signalling through glycogen synthase kinase-3. Immunology 130: 556-563, 2010.
34. Eom TY, Roth KA and Jope RS: Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3. J Biol Chem 282: 22856-22864, 2007.
35. Yang TT, Chen CL, Lin WC, Lin YS, Tseng PC, Hsieh CY, Chen YH, Huang WC, Tsai CC, Wang CY, Shieh CC and Lin CF: Glycogen synthase kinase-3 inactivation is an intracellular marker and regulator for endotoxemic neutrophilia. J Mol Med (Berl) 91: 207-217, 2013.
36. Gustafson WC and Weiss WA: Myc proteins as therapeutic targets. Oncogene 29: 1249-1259, 2010.
37. Jing YY, Han ZP, Sun K, Zhang SS, Hou J, Liu Y, Li R, Gao L, Zhao X, Zhao QD, Wu MC and Wei LX: Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. BMC Med 10: 98, 2012.
38. Liu WT, Jing YY, Yu GF, Han ZP, Yu DD, Fan QM, Ye F, Li R, Gao L, Zhao QD, Wu MC and Wei LX: Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma. Cancer Lett 358: 136-143, 2015.
39. Le Floch N, Rivat C, De Wever O, Bruyneel E, Mareel M, Dale T and Gespach C: The proinvasive activity of WNT-2 is mediated through a noncanonical Wnt pathway coupled to GSK-3 and c-JUN/AP-1 signaling. FASEB J 19: 144-146, 2005.
40. Santaolalla R, Sussman DA, Ruiz JR, Davies JM, Pastorini C, España CL, Sotolongo J, Burlingame O, Bejarano PA, Philip S, Ahmed MM, Ko J, Dirisina R, Barrett TA, Shang L, Lira SA, Fukata M and Abreu MT: TLR4 activates the catenin pathway to cause intestinal neoplasia. PLoS One 8: e63298, 2013.